Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published April 2019
  • Article
  • Info & Metrics
  • PDF
Loading

A covalent-binding, selective inhibitor of HER2 kinase

Irie et al. Page 733

HER2 is a promising therapeutic target for various cancers. Although several reports have described HER2 inhibitors, no covalent-binding inhibitor selective for HER2 kinase has been reported. The high specificity for HER2 kinase inhibition may prevent EGFR-related toxicity and achieve more effective dosing in HER2-targeted therapy. In this study, Irie and colleages demonstrated TAS0728 was a covalent-binding kinase inhibitor that showed the high selectivity for HER2 and reduced activity for EGFR. These results may provide a rationale to offer a new therapeutic option for the treatment of cancers harboring HER2 gene abnormalities.

Effective bladder tumor growth control by PDT with THPTS

Berndt-Paetz et al. Page 743

The recommended therapy for muscle-invasive urothelial cancer includes radical cystectomy with or without chemotherapy. Photodynamic therapy (PDT) presents a promising option as an organ-sparing therapy for muscle-invasive urothelial cancer but is limited by the short excitation wavelengths of typical photosensitizers. In this study, Berndt-Paetz and colleagues utilize the near-infrared excitation wavelength of the photosensitizer Tetrahydroporphyrin-Tetratosylat (THPTS) to penetrate up to 15 mm into tissue. They demonstrated that PDT with THPTS generates tumor reductions in an immunocompetent rat model of muscle-invasive urothelial cancer while sparing healthy tissue. These results suggest PDT with the photosensitizer THPTS is worthy of clinical consideration as an organ-sparing therapy in muscle-invasive urothelial cancer.

P16/CDKN2A predicts CDK4/6 inhibitor target engagement and sensitivity

Green et al. Page 771

While CDK4/6 inhibitors have demonstrated therapeutic efficacy for ER+/HER2- advanced breast cancer, biomarkers are still needed to predict patient response and to extend the treatments to other cancers. Here, Green and colleagues assessed CDK4/6 target engagement in a panel of cell lines with known CDKNK2A-CDK4 binding alterations and found that the interaction limits target engagement by CDK4/6 inhibitor drugs. Further research showed that high CDKN2A correlated with a biological insensitivity in a diverse panel of cell lines, but not in the ER+ subset. Therefore, high p16/CDKN2A could serve as an ER-independent biomarker to identify patients unlikely to respond to CDK4/6 inhibitors.

The tumor-growing mice may take antibodies away

Li et al. Page 780

Preclinical assessment of therapeutic antibodies relies on immune-deficient mouse strains, which allow various tumor models to engraft. However, the choice of these mice may have impact on the pharmacokinetics profile. In this study, Li and colleagues contrast the half-life of antibodies in various mouse models. Surprisingly, the half-life of an antibody was only 1.4 days in the NSG mice, in contrast to a 7-day half-life in other strains. Mechanic studies found that Fc-FcγR interaction was responsible for the abnormal clearance in NSG mice. This shortened exposure resulted in reduced efficacy of an antibody-drug conjugate in NSG mice. The authors propose to pretreat mice with immunoglobulin to normalize antibody pharmacokinetics. Integrating strain-specific clearance parameters may help better guide the dose selection for clinical studies.

  • ©2019 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 18 (4)
April 2019
Volume 18, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther April 1 2019 (18) (4) 731;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther April 1 2019 (18) (4) 731;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • A covalent-binding, selective inhibitor of HER2 kinase
    • Effective bladder tumor growth control by PDT with THPTS
    • P16/CDKN2A predicts CDK4/6 inhibitor target engagement and sensitivity
    • The tumor-growing mice may take antibodies away
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement